Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stock Position Lifted by Barclays PLC

Barclays PLC grew its position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 320.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 16,146 shares of the company’s stock after buying an additional 12,308 shares during the period. Barclays PLC owned about 0.11% of Jasper Therapeutics worth $304,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of JSPR. Bank of New York Mellon Corp bought a new position in Jasper Therapeutics during the 2nd quarter worth approximately $740,000. Rhumbline Advisers acquired a new stake in shares of Jasper Therapeutics during the 2nd quarter worth approximately $300,000. American Century Companies Inc. raised its position in shares of Jasper Therapeutics by 27.1% during the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after purchasing an additional 3,032 shares during the period. Wolff Wiese Magana LLC acquired a new stake in shares of Jasper Therapeutics during the 3rd quarter worth approximately $59,000. Finally, Fernwood Investment Management LLC raised its position in shares of Jasper Therapeutics by 6.9% during the 3rd quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock worth $995,000 after purchasing an additional 3,427 shares during the period. Institutional investors own 79.85% of the company’s stock.

Analysts Set New Price Targets

JSPR has been the topic of a number of research reports. BMO Capital Markets initiated coverage on Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $65.00 price target on shares of Jasper Therapeutics in a research report on Thursday, October 24th. Royal Bank of Canada reiterated an “outperform” rating and set a $68.00 price target on shares of Jasper Therapeutics in a research report on Monday, December 23rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. Finally, JMP Securities reiterated a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, October 15th. Ten research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $73.38.

Jasper Therapeutics Price Performance

JSPR opened at $19.27 on Monday. Jasper Therapeutics, Inc. has a 12 month low of $6.50 and a 12 month high of $31.01. The stock has a market cap of $289.07 million, a P/E ratio of -4.07 and a beta of 2.18. The stock’s 50 day moving average price is $22.07 and its 200 day moving average price is $20.50.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.